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This study aims to establish thebest and simplified panel ofmolecularmarkers for prognostic stratificationof glioblastomas
(GBMs). One hundred fourteen cases of GBMs were studied for IDH1, TP53, and TERT mutation by Sanger sequencing;
EGFR and PDGFRA amplification by fluorescence in situ hybridization; NF1expression by quantitative real time polymerase
chain reaction (qRT-PCR); and MGMT promoter methylation by methylation-specific PCR. IDH1 mutant cases had
significantly longer progression-free survival (PFS) and overall survival (OS) as compared to IDH1 wild-type cases.
Combinatorial assessment of MGMT and TERT emerged as independent prognostic markers, especially in the IDH1
wild-type GBMs. Thus, within the IDH1 wild-type group, cases with only MGMT methylation (group 1) had the best
outcome (medianPFS: 83.3weeks;OS: not reached),whereasGBMswith only TERTmutation (group3) had theworst
outcome (PFS: 19.7 weeks; OS: 32.8 weeks). Cases with both or none of these alterations (group 2) had intermediate
prognosis (PFS: 47.6weeks;OS: 89.2weeks).Majority of the IDH1mutantGBMsbelonged to group 1 (75%),whereas
only 18.7% and 6.2% showed group 2 and 3 signatures, respectively. Interestingly, none of the other genetic
alterations were significantly associated with survival in IDH1 mutant or wild-type GBMs.
Based on above findings, we recommend assessment of three markers, viz., IDH1, MGMT, and TERT, for GBM
prognostication in routine practice. We show for the first time that IDH1 wild-type GBMs which constitute majority of
the GBMs can be effectively stratified into three distinct prognostic subgroups based on MGMT and TERT status,
irrespective of other genetic alterations.
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Glioblastoma (GBM), the most common malignant primary brain
tumor in adults, has a diverse prognosis despite aggressive therapeutic
intervention [1,2]. There has been a great increase in the
understanding of molecular alterations, both genetic and epigenetic,
in GBMs. However, the number of clinically relevant molecular
markers for GBM prognostication remains limited. Also, the best
panel of molecular markers to be used in routine practice remains
debatable. Among the molecular alterations, isocitrate dehydrogenase
1 (IDH1) mutation has been shown to be a prognostic marker
372 Simplified Prognostic Stratification of GBMs Purkait et al. Translational Oncology Vol. 9, No. 4, 2016associated with longer overall (OS) as well as progression-free survival
(PFS) [3–5]. The methylation of the O-6-methylguanine-DNA
methyltransferase (MGMT) promoter is another well-established
prognostic and predictive marker [6]. Recently, mutations in the
promoter region of telomerase reverse transcriptase (TERT), the gene
encoding catalytic subunit of telomerase, have been described in
gliomas especially in GBMs and correlated with poor clinical outcome
[7–10]. Few recent studies have suggested various prognostic
subgroups. Thus, Molenaar et al. [11] reported a two-gene predictor
for GBM survival and, based on the combination of IDH1 and
MGMT status, stratified GBMs into three prognostically distinct
genotypes. Another study by Kellia et al. [12] demonstrated three
prognostic molecular subgroups of GBMs based on TERT and IDH1
status. Recently, Eckel-Passow et al. [13] combined TERT mutation
with IDH1 mutation and 1p/19q co-deletion status and described
five distinct prognostic subgroups of gliomas. GBMs having only
IDH1 mutation had the best prognosis, whereas those with TERT
mutation only had the worst PFS/OS [13]. However, the drawback of
all these studies is that they do not simultaneously incorporate other
important genetic alterations in GBMs such as TP53 mutations and
RTK and NF1 alterations for survival analysis, which may be
important confounding factors in determining clinical outcomes.
Hence, the present study was undertaken to assess the key genetic
alterations in GBMs (viz., amplification of EGFR and PDGFRA and
mutation of IDH-1, TP53, and NF-1 genes), along with MGMT
promoter methylation and TERT mutation status, to determine their
prognostic significance in combination and thus identify the best
panel of markers for prognostication of GBMs.
Material and Methods
All cases diagnosed as GBMs between 2006 and 2012 were identified
from a detailed review of records of the Neuropathology Laboratory
of the Department of Pathology, All India Institute of Medical
Sciences, New Delhi, India. Cases of adult GBM wherein adequate
tumor tissue was available in formalin-fixed, paraffin-embedded
(FFPE) blocks along with snap-frozen tumor tissue stored at −80°C
were taken up for the study. All experiments using patient samples
were approved by the ethics committee of All India Institute of
Medical Sciences, New Delhi. Hematoxylin and eosin–stained slides
of these cases were reviewed, and a concordant agreement was
established for the confirmation of the diagnosis between three
experienced histopathologists based on the WHO classification
(2007). Based on these criteria, 114 cases of GBMs were selected for
the present study.
Patient Data
Patient records were reviewed to obtain demographic data,
including age, sex, tumor location, treatment received, and
follow-up. The cases were divided into young adult (age ≤ 40 years)
and older adult groups (age N 40 years). All the patients included for
survival analysis (n = 73) underwent total to near-total surgical
resection and received radiotherapy along with concurrent chemother-
apy and had a Karnofsky Performance Score (KPS) of ≥70.
Postoperative radiation therapy was started within 4 to 6 weeks of
surgery. A dose of 50 Gy in 25 fractions was prescribed for CTV1
(enhancing tumor +edema+2.5-cm margin all around as seen in the
preoperative T2-weighted magnetic resonance imaging scan) followed
by a boost of 10 Gy in 5 fractions over 1 week. Concurrent
temozolomide was given at a dose of 75mg/m2 daily in empty stomachfollowing antiemetic and ranitidine 1 hour before radiation. The
maintenance temozolomide was started after a gap of 1 month in
patients without any recurrence. The first cycle was given at 150mg/m2
and, depending on the tolerance, increased to 200 mg/m2 in the next
cycle for a minimum of 6 cycles every 4 weeks. The incidence date was
defined as the date of surgery. The recurrences were defined as the cases,
which showed evidence of progression by magnetic resonance imaging
that required a second resection or adjuvant treatment. Patient outcome
was characterized in terms of PFS and OS.
IDH1, TP53, and TERT Gene Mutation Analysis by
Sanger Sequencing
For sequencing analysis, DNA was isolated from frozen tumor
tissue using standard protocol. For TP53 mutational analysis, coding
regions from exons 2 to 11 were evaluated using the direct sequencing
protocol as described in the International Agency for Research on
Cancer p53 database and described earlier [14]. Mutations in exon 4
of IDH1 were determined by direct sequencing in all the cases as
described in the previous study [15].
For TERT mutation, the forward primer TERT-F (5′-GTCCT
GCCCCTTCACCTT-3′) and reverse primer TERT-R (5′-CAGCG
CTGCCTGAAACTC-3′) were used to amplify a 163-bp fragment
spanning the two mutational hotspots [chr5, 1 295 228 (C228T) and
1 295 250 (C250T)] in TERT promoter region. Polymerase chain
reaction (PCR) was performed in a total of 25 μl using 0.3 mM of
each dNTP, 2.5 mMMgCl2, 0.3 mM of each primer, 0.2 U of DNA
polymerase, and 10 ng of DNA in 25 μl of reaction mixture. PCR
product was further purified and cleaned using ExoSAP as per
manufacturer’s protocol. Subsequently, 2 μl of the purified
amplification product was submitted to bidirectional sequencing
using the BigDye Terminator Cycle Sequencing kit v1.1 (Life
Technologies). The products were resolved in Genetic Analyzer
3130xl and analyzed by Sequencing Analysis software.
Analysis of NF-1 Expression using Real-Time PCR
As sequencing of NF1 gene is difficult owing to the large size and
multiple mutation hotspots, downregulation of NF-1 mRNA expression
(expression ≤ 0.5 folds of control) was considered as a signature marker
of gene mutation. RNA was extracted from frozen tissue specimens by
using commercially available mirVanamiRNA Isolation Kit (M/S.
Ambion, USA) following manufacturer's protocol. One microgram of
the total RNA from all samples was reverse-transcribed to cDNA using
SuperScript VILO cDNA Synthesis Kits (Life Technologies). To
determine the expression profile of NF1, real-time PCR was performed
using primers designed via Primer3 software (v.0.4.0) [5′-
GCATTTCTACCAGTAACCTTGATGATAC-3′ (F) and
5′-TCTGAACAAACAGTTAATTCCTGTAACC-3′ (R)]. Quantifi-
cation was performed on Light Cycler 480 (Roche Diagnostic, Basel,
Switzerland) using SYBR-Green chemistry. Expression levels of mRNA
were calculated using comparative cycle threshold (Ct) method. Ct
values of the target mRNAs were normalized in relation to reference
genes (TATA Box Binding Protein). The fold change was calculated
using the equation 2−ΔΔCt.
Assessment of EGFR and PDGFRA Amplification Using
Fluorescence In Situ Hybridization (FISH)
FISH analysis was carried out on FFPE sections as previously
described [16]. Briefly, a dual-color FISH assay was performed on
paraffin-embedded sections with a locus-specific probe for EGFR
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probe for chromosome 7 (spectrum green) (M/S Vysis, Inc.). For
analysis of PDGFRA amplification, Tricolor Rearrangement Probe
was used (Spectrum Aqua for PDGFRA, Spectrum Green and Orange
for control) (M/S Vysis, Inc.). Signals were enumerated in 200
nonoverlapping nuclei. Amplification was considered when N10% of
tumor cells showed either test:control signal ratio N2 or innumerable
tight clusters of signals of the locus probe.
Assessment of MGMT Promoter Methylation Status
Using Methylation-Specific PCR
DNA methylation pattern of the MGMT gene promoter was
determined by methylation-specific PCR. This procedure involved
chemical modification of unmethylated cytosine to uracil, followed
by a nested two-stage PCR. The detailed procedure has been
described in the previous study [17].
Statistical Analysis
Statistical tests were carried out using SPSS version 17 software
(SPSS Inc., Chicago, IL) or Excel (Microsoft). Chi-square test and
Fisher’s exact test were applied to examine the association between the
qualitative variables. To test the relationship with continuous
variables, the Mann-Whitney U test was used. PFS and OS were
calculated from the incidence date until the date of recurrence or
death (PFS) or the date of death due to tumor (OS). Patients who
were recurrence-free at the last follow-up were considered as a
censored event in the analysis. To assess clinical and/or molecular
alteration associated with PFS, survival curves were calculated
according to the Kaplan-Meier method, and the differences between
curves were assessed using the log-rank test. Variables with a
significant P value were used to build a multivariate Cox model. In all
analysis, two-sided P values less than .05 were considered significant.
Results
Patient Characteristics
The study included 114 cases of adult supratentorial GBMs. The
mean age at diagnosis was 48 years (range: 21-77 years), and the male
to female ratio was 2.3:1. Majority (67.5%; 77/114) of the patients
were older adults (N40 years), whereas the rest (32.5%; 37/114) were
young adults (≤40 years). Follow-up was available in 73 cases, and
median PFS and OS were 56.1 weeks and 83.3 weeks, respectively.
The young adult patients (n = 24) had a significantly better survival as
compared to older adults (n = 49) [median PFS: 69.7 weeks vs 45.4
weeks; medianOS: not reached (NR) vs 83.3 weeks] (Figure 1,A andB).
MGMT Promoter Methylation, TERT Mutation Status,
and Correlation with Age and Prognosis
MGMT status was assessed in theGBMcases with follow up (n = 73).
Methylation of MGMT promoter was identified in 48.6% (36/73) of
cases. This epigenetic alteration did not show any association with age.
The frequency of MGMT promoter methylation was significantly
higher in IDH1 mutated cases (81.3%; 13/16) as compared to IDH1
wild-type (40.4%; 23/57) (P value = .005). As a corollary, 36% (13/36)
of theMGMTpromotermethylated cases showed IDH1mutation. The
cases with MGMT promoter methylation also had significantly longer
survival as compared to unmethylated cases (median PFS: 82.7 weeks vs
23.8 weeks; median OS: NR vs 58.3 weeks) (Figure 1, C and D).
TERT promoter mutation was identified in 51% (37/73)
of cases which included 72% C228T and 28% C250T mutations.This genetic alteration was significantly more common in older adults
as compared to young adults (61.2% vs 25%; P value = .006). On
correlation with molecular alteration, TERT mutation was found to
be extremely rare in IDH1 mutated group (12.5%; 2/16) (P value =
.001), whereas it was more commonly associated with EGFR
amplification (74%; 17/23) and NF1 alteration (66.7%;12/18). The
cases with TERT mutation had significantly shorter survival as
compared to those with TERT wild-type (median PFS: 32.8 vs 82.5
weeks; median OS: 58.3 weeks vs NR) (Figure 1, E and F).
Frequency of Genetic Alterations and Correlation with Age
The frequency of genetic alterations, age distribution, and prognostic
outcome of each genetic alteration separately is depicted in Table 1. EGFR
amplification was most frequent (40%), whereas TP53, IDH1, and NF1
mutations were noted in approximately 20% of cases each. Furthermore,
IDH1mutation, TP53 mutation, and PDGFRA amplification were more
prevalent in young adults, whereas EGFR amplification andNF1 alteration
were commoner in older adults. No significant association was identified
between different genetic alterations with site and gender.
Prognostic Stratification Based on Molecular
Genetic Alterations
For prognostic stratification, we first subdivided GBM cases into IDH1
mutant and IDH1wild-type. IDH1mutated cases had significantly longer
survival as compared to IDH1 wild-type cases (median PFS: 91.3 vs 40.7
weeks; median OS: NR vs 61.7 weeks) (Figure 1, G and H). Next, the
IDH1 wild-type cases were further prognostically subclassified based on
EGFR, PDGFRA, TP53, and NF1 status. Interestingly, there was no
significant difference among these genetic subgroups in terms of survival
(Table 2; Figure 1, I and J). In the IDH1mutant group, none of the cases
showedEGFR/PDGFRA amplification orNF1 downregulation. A total of
42.1% (8/19) of cases showedTP53mutation, but there was no significant
correlation with prognosis.
Combinatorial Assessment of IDH1, MGMT,
and TERT for Prognostication
Next, we assessed the combinatorial prognostic implication of TERT
andMGMTin IDH1mutant andwild-type cases. Interestingly, the IDH1
wild-type group could be effectively divided into three distinct prognostic
subgroups based on MGMT and TERT status, with cases showing only
MGMT promoter methylation (group 1; n = 12) having the best outcome
(median PFS and OS: 83.3 weeks and NR) and cases with only TERT
mutation (group 3; n = 24) having the worst prognosis (median PFS and
OS: 19.7 and 32.8 weeks). The prognosis of the cases with both these
alterations (double positive) or none of these alterations (double negative)
was intermediate between the above-mentioned groups. Hence, these two
groups were clubbed together as group 2 (median PFS and OS: 47.5 and
89.2 weeks) (Figure 1, K and L). On multivariate analysis also, these
prognostic subgroups showed similar association with survival irrespective
of other genetic alterations and age (Table 3).
In the IDH1 mutant group, TERT mutation was rare and only a
single case belonged to group 3; hence, it was excluded for analysis.
However, cases with only MGMT methylation (group 1; n = 12)
demonstrated a trend toward better survival than group 2 (n = 3)
[hazard ratio (HR): 1.47 and 1.22, respectively, for PFS and OS].
However, the difference was not statistically significant possibly
because of the small number of cases in group 2.
Thus, the most important panel for prognostication in GBMs
appears to be a combination of IDH1, MGMT, and TERT. Majority
Figure 1. PFS and OS represented by Kaplan-Meier plots for young versus older adult age group (A, B); MGMT promoter methylated
versus unmethyalted cases (C, D); TERT mutated versus wild-type cases (E, F); IDH1 mutated versus wild-type cases (G, H); EGFR,
PDGFRA, TP53, and NF1 alterations in IDH1 wild-type cases (I, J); and three prognostic subgroups of GBMs based on MGMT and TERT
status in IDH1 wild-type group (K, L).
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stratification based on MGMT and TERT is indeed very important.
Discussion
GBMs are extremely heterogeneous tumors with multiple complex
genetic abnormalities. Among various prognostic biomarkers, IDH1-
mutations appeared most important and defined a distinct subgroup ofGBMswith favorable outcome [18,19]. Similarly, the present study also
highlighted the prognostic significance of IDH1. However, other
molecular genetic alterations, namely, TP53 mutation, NF1 mutation,
EGFR amplification, and PDGFRA amplification, did not demonstrate
any significant association with survival in the IDH1 wild-type group.
MGMT promoter methylation status has been one of the well-known
positive prognostic as well as an independent predictive marker for
Table 1. Frequency and Demographic Profile of Different Genetic Alterations
Molecular Alteration Frequency Age (Years) Mean (Range) M:F
IDH1 mutation 16.7% (19/114) 37 (22-60) 8.5:1
TP53 mutation 16.7% (19/114) 41 (21-66) 8.5:1
PDGFRA amplification 8.8% (10/114) 35 (23-55) 4:1
NF1 downregulation 21% (24/114) 52 (28-74) 2.1:1
EGFR amplification 39.5% (45/114) 54 (38-77) 2.2:1
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relevance for prognostication of GBMs was also confirmed in the
present series. TERT is another frequently mutated gene in GBMswith
prognostic implication. In the present study, the frequency of TERT
promoter mutation was slightly lower as compared to the reported
Western literature. However, similar to previous studies, this genetic
alteration was found to be significantly more frequent in older adults as
compared to young adults [8]. Hence, the lower frequency of TERT
promotermutation in the present seriesmay be attributable to the lower
mean age of our cohort. Our data also showed that TERTmutation was
associated with poorer outcome inGBMs, consistent with previous data
on gliomas [12].
Few studies in recent years have prognostically stratified GBMs
based on combination of various biomarkers. Interestingly, all these
studies included IDH1 mutation in the marker panel for
prognostication. Based on the IDH1 and MGMT status, Molenaar
et al. [11] stratified GBMs (n-98) into three prognostically different
subgroups. Patients with IDH1 mutation and MGMT methylation
had the longest survival, followed by patients with IDH1 mutation or
MGMT methylation alone, whereas patients without both these
alterations had the shortest survival. Similar prognostic stratification
using MGMT and IDH1 was also described by Hartmann et al. [21]
in cases of high-grade astrocytoma (grade III and IV; n = 338).
Interestingly, the authors did not observe any significant difference in
prognosis between IDH1 wild-type GBMs and anaplastic astrocyto-
mas. Killela et al. [12] analyzed IDH1/2 and TERT status in 415
cases of gliomas of different grades and showed that, based on these
genetic alterations, grade III and IV tumors can be effectively
classified into four prognostic subgroups irrespective of tumor
histomorphology and WHO grade. The cases with both TERT
and IDH mutation (morphologically oligodendroglioma) had the
best prognosis, whereas cases with only TERT mutation had the
worst prognosis. Interestingly, within the GBM group, concomitant
IDH and TERT mutation was extremely rare. Hence, GBM cases
were subdivided into three prognostic subgroups. Cases with only
IDH mutation had the best prognosis (OS = 42.3 months), followedTable 2. Correlation of EGFR, TP53, NF1,and PDGFRA Status with PFS and OS in IDH1 Wild-T
Genetic Alterations Median PFS (Wks) P Value
Only TP53 mut (n = 4) 59.1 TP53 vs EGFR
TP53 vs PDGR
EGFR amp (n = 23) 40.7 TP53 vs NF1
TP53 vs none
PDGFR amp (n = 6) 28.8 EGFR vs PDG
EGFR vs NF1
NF1 (n = 18) 35.1 EGFR vs none
NF1 vs PDGF
None (n = 6) 47.3 NF1vs none =
PDGFRA vs nby cases with IDH/TERT wild-type (16.6 months) and only TERT
mutation (11.3 months). Recently, Eckel-Passow et al. [13]
subdivided 1087 cases of gliomas (615 grade II or III and 472
grade IV) based on IDH, TERT, and 1p/19q co-deletion. Among the
GBMs, majority (74%) showed only TERT mutation, 17% were
triple negative, 7% had only IDH mutation, and only 2% showed
combined TERT and IDH mutation. Similar to the previous studies,
cases with only IDH1 mutation had the best and cases with only
TERT mutation had the worst survival.
All the above-mentioned studies including ours highlight the
importance of IDH in prognostic stratification of GBMs. Unfortu-
nately, IDH1 mutation is rare in primary GBMs and seen mainly in
secondary GBMs which constitute only 10% to 15% of all GBMs
[22].On the other hand, there is considerable heterogeneity among
the IDH1 wild-type cases in terms of clinical outcome, indicating the
necessity of further stratification. For the first time, the present study
demonstrated that IDH1 wild-type cases which constitute majority of
GBMs (approximately 83% in present series) can effectively be
subclassified into three prognostic subgroups based on MGMT and
TERT status. Interestingly, IDH1 wild-type cases with only MGMT
methylation (group 1) had survival similar to the IDH1 mutated
cases, whereas IDH1 wild-type cases with TERT mutation
demonstrated worst survival. IDH1 mutated cases need not be
further stratified based on MGMT and TERT because majority of
these cases are MGMT methylated and rarely have TERT mutation.
Therefore, based on the results of the present study, we
recommend routine assessment of a panel of only three markers,
namely, IDH1 mutation, MGMT promoter methylation, and TERT
mutation status for GBM prognostication. All cases of GBMs should
be analyzed for IDH1mutation first by Sanger sequencing or
immunohistochemistry with mutant-specific antibody followed by
assessment of TERT and MGMT status especially in IDH wild-type
cases. All these assessments require a small quantity of tumoral DNA
and can be done on DNA extracted from FFPE tissue. The
International Society of Neuropathology-Haarlem Consensus Guide-
lines state that “It is also entirely possible that genetic tests not
discussed at this meeting (eg, TERT mutation) will be incorporated
into diagnostic definitions at the time of the eventual WHO
classification revisions” [23]. Our study thus supports the incorporation
of these tests into the final revised WHO classification.
Acknowledgements
The authors are thankful to the Indian Council of Medical Research
and Neuro Sciences Centre for funding.ype GBMs (n = 57)
Median OS (Wks) P Value
= .06 Not reached TP53 vs EGFR = .06
R = .11 TP53 vs PDGRR = .22
= .31 58.3 TP53 vs NF1 = .14
= .88 TP53 vs none = .41
FRA = .23 47.5 EGFR vs PDGFRA = .97
= .38 EGFR vs NF1 = .22
= .24 83.2 EGFR vs none = .42
R = .35 NF1 vs PDGFR = .90
.30 Not reached NF1 vs none = .63
one = .19 PDGFRA vs none = .61
Table 3. Prognostic Subgroup of IDH1 Wild-Type GBMs Based on MGMT and TERT Status
Prognostic Subgroups PFS OS
Univariate Analysis Multivariate Analysis* Univariate Analysis Multivariate Analysis*
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Gp1− MGMT+/TERT− (n = 12) Reference – Reference – Reference – Reference –
Gp2− both+/both− (n =21) 2.97 (0.97-9.09) .05 2.67 (0.81-8.75) .10 3.45 (0.79-14.95) .09 2.42 (0.42-13.97) .32
Gp3− MGMT−/TERT+ (n = 24) 11.95 (3.81-37.51) b .001 10.44 (3.21-33.09) b .001 23.83 (5.43-104.47) b .001 11.12 (1.99-61.99) .006
* Adjusted for age and other genetic alterations.
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